Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The other day I saw bids\asks at 6 decimal points out. Ridiculous! I don’t think we saw that when the price was 15 cents! Hope you get your shares. My advise: It’s not worth holding out for a thousandth of a cent..
Hank, I had something similar happen to me, where I placed a buy order on the ask and it didn't fill. Finally, I placed it slightly above the ask and it still didn't fill, but other orders were filling. I called my brokerage firm (Vanguard) and they called the MM and it filled within 15 minutes.
Alphavestcapital.com just added a credit to Superstonk (Reddit) to the top of the article we've been talking about.
alphavestcapital.com
@alphavestcap
·
53m
$nwbo
@alphavestcap
insert-text-here
I want to make a small correction to my description of "batch" yesterday. What I said about "batch" is actually true for DCVax-L: a batch contains all the vaccines made for a single patient at one time, remembering that each patient's vaccines are made from his/her own cells. However, globally, "batch" refers to all the pills, etc., that are made in a single run by a Pharma, which could be hundreds or thousands. Each "batch" needs to be checked for imperfections. That's why we spend more on quality control because each "batch" is one patient for our product, but still must be checked by a quality control person. Eden will reduce the cost of our quality control by creating a closed system.
I hope management is sending this to Laura and our team of lawyers on the MM spoofing case! Hopefully, they are already on it!
Thanks, Red_Right_Hand, for posting what appears to be the original on Reddit/Superstonk. And it appears to be part of a series of articles on Reddit under r/Superstonk, though I'm not sure how to get to the first two articles. I still can't tell who the writer is. Perhaps "thabat" ??
I don't know how to post a link to X (Twitter), but I'd suggest longs might want to check out alphavestcapital.com over there. It looks like this is the work of Alpha, but I'm not sure. Under it, it looks like this was posted on the Superstonk community on Reddit. I don't know much about online communities, so I'll let one of you sort out who the author is. I'd like to give credit where it is due. There's a whole bunch of stuff on alphavestcapital.com that I don't understand.
I don't have any comment on whether what Alpha posted. I'm interested to hear what the experts here on iHub think.
TIA
Alphavestcapital.com on Twitter has posted this about our MMs and why they are hitting on NWBO:
OTCN had a 198,055 sell order at .33 that just disappeared, followed by the price going slightly down. Was it real or a spoof? CDEL has. 198,000 sell at .34. Just curious if MM's are tamping down excitement. Any thoughts?
I hate to say it but I fear you're right, Flipper. They will play the short until the day of approval and, perhaps, until the day we report earnings in the multi-millions. But if buyers begin to overwhelm the shorts, that's another story and we could see price begin to rise on high volume. Thanks for your imput. I would not be surprised if it takes a few more weeks.
Flipper:
Horseb4carT, If there was any doubt about marketing approval, I think it's gone now. No point in MHRA approving our manufacturing plant for production of our DCVax-L if they're not going to approve DCVax-L. Whether the approval comes tomorrow or a few weeks from now is almost unimportant. It's happening, Folks!
IMHO
BTW, does anyone know if Les is talking on Big Biz soon? I know it was discussed a few days ago.
Horse:
Crash, Batch means the vaccines are made together as a batch, then separated into vials for use over the next three years or so after they have been processed. I'm pretty sure of that. This is done whether by artisan method or Eden. I don't see any indication that Flashworks' Eden has been approved, but please prove me wrong!
Tryn2, I'm ready for that short squeeze!!
Talking about how toxic radiation/chemo is....My brother-in-law worked for the Department of Energy heading a group that handled nuclear material in potential threats of terrorism. If someone found a "hotspot", his team was called in to deal with what could be a nuclear threat. One time they picked up a hotspot coming from a car that was leaving a hospital. Thinking it was a terrorist stealing nuclear material from a hospital, they followed the car back to a house where an older woman got out of the vehicle. Turns out, doctors had zapped her with so much radiation, she was lighting up their radiation devices. Needless to say, it was way over the limit of what they should have given her.
Our health care system at work!
That's what I thought, too, attilathehunt.
Thanks, Astavaka, for this excellent AI response to the roles of MHRA and the CHM on MAA, (basically confirming what Red Right Hand told us). One of these days I guess I'll have to learn how to use these AI tools.
549K, as well as a 150K and 5 trades around 70K. Trades in the 40k range and 20K. Lots of big trades! Why the big numbers? Is a big whale getting in or are shorts covering and leaving? I suspect the 549K was bought over time today.
Red_Right_Hand, Thanks for the correction. It appears you're right. I just assumed that since the MHRA seemed to be linking dates,etc., to the CHM meetings that they were collecting the information, as well. Instead, they are the experts in the specific areas of medicine that the MHRA receives input from before making their own decision.
In the following comment from the MHRA site, an "assessment team" is referenced. It's the only place I've seen it mentioned. Perhaps this is the group that does the actual legwork.
DJPele, This CHM meeting is also the first such meeting since we passed 210 days since our MAA was validated on Jan. 24th. The CHM (Committee on Human Medicine) is the committee that examines the MAA and does all the legwork for the MHRA, including inspections, and presents the evidence they've gathered to the MHRA board on whether to approve a new treatment. If the MHRA is on schedule, this should be the meeting where the CHM finalizes its report. However, we know that MHRA has struggled to stay on schedule. So, I have fingers crossed that we're almost there. However, I don't expect to hear about approval until MHRA has had the time to receive the report from the CHM, examine it and vote on it. I personally was not able to find any day of the week or month specifcally set aside for the MHRA board to meet and decide on new medicine applications. So, perhaps they decide as they receive CHM reports on MAAs.
I'm thinking first half of September for MHRA decision. If not, we get to start hoping that the September CHM meeting is the golden one, with decision in early October.
abc, thank you for writing this very succinct post:
Hi TopelRoad, I don't see a PR about any audits. Can you explain this statement and tell us where to find the audits? And who are "they" and what are they auditing?
Thanks. I'm on the road and feel like I missed something.
TopelRoad:
They also PR ed a set of audits. So scheduling, actual audit, 30 days to deliver report, 30 days to respond to report, potential back and forth, and finalisations.
Audit is one of the last requirements.
BB, I have not found anything on BIOS. Can you direct me to their site or tell us more about them? Or was there an original post about them here on iHub that I missed? (I'm on the road). Are they a stock analyst company and did they replace the pull of the short recommendation with any other recommendation? Thanks for all your posts! I'm really enjoying them now!
Doc, I'm hoping the first Eden units arrive in the next few months, or at least by January! Yes, 17 months from now we should be riding a high in mood and money with all the accomplishments our little biotech should have made by then!
Meirluc, I agree with you that I also thought Les had no way of knowing when MHRA would make a decision but everyone else thought he was commenting on MAA decision.
I think the biggest problem we've had with Les on Big Biz is that he talks slowly and runs out of time. The most important info for us, who know all the past, is his last few comments dealing with the future, and they're always cutting him off at the end. I wish he would state the important, newer stuff first, then fill the newbies in on the details! Hopefully we won't be enduring many more of those shows!
Yeah, Flipper, we all could have used an 8K on that big blunder.
Linda has been speakig about building a franchise but has not actually defined how she envisions this franchise operating. So, we're all left to our own thoughts of how a franchinse will work with NWBO.
Here are two comments about "franchise" in recent PRs. I believe there are others, but only took a quick look round.
June 17, 2024 PR on in-licensing
About that "fall" comment by Les...
From our friend, Dr. Greg Z (Iamadiver) on X/Twitter
Thanks, Georgebailey. 500-550 was the original number of patients that can be done in our 1A suite. If they have 1B up and running, you're right: that doubles the patient load to 1000 or so. Hopefully, we're there, but I'm not sure management has told us that yet.
Stacking the Eden units? I'd leave that decision up to the experts, skitahoe.
Thanks, Maverick_1, for another correction on the number of GBM cases in the UK.
According to Dr. Paul Mulhholland:
A big Thank You!, Lykiri, for correcting my memory/guess at what I thought was the number of new GBM cases in the UK each year. Professor Ashkan has the number on his presentation as 4,500 new GBM patients per year in the UK. That's a much bigger number than the 1,500 I thought I remembered Linda stating. So, much more reason to get Flaskworks' Eden system manufactured and validated for use soon!! Very soon after/by MAA approval, which us longs expect to see!
Hi Doc Logic,
I agree with the first part of what you said, but I'm not sure what you were referring to by this comment:
Wow! great catch finding those new job listings, aperture.
Good hearing from you!
Meiluc, I expect/hope the artisan method will be used at least 2 to 6 months ahead of when the first few Edens are expected to be up and running. I also expect that we will not be through the inspections until at least the end of this month and probably through part or all of September. I say this based on the way the 10Q read: they wrote that the inspections were scheduled. It was not written to indicate they were in the midst of doing inspections. However, I felt like the inspections were imminent because of how the language had changed from the last 10Q and that management now has a handle on not only when and where they'll take place, but also how many inspections will be done. Consequently, there was far less emphasis in this 10Q on mock inspections and no talk of getting everybody, everyplace, everywhere ready.
August 2024:
Yes, dstock. There's no combination trials between Roswell technology and DCVax-L. The three trials are totally Roswell and U. of Penn. technology (maybe). And they are all 3 up and running with the 3rd just recently taking patients. So in Clinical Trials, they will all be under Roswell and perhaps U. of Penn., which if I remember correctly, is the other place that was developing this technology by Pawel Kalinski and which we bought last year.
Doc Logic, I believe MHRA needs to see that our Flaskworks Eden units work before we get a green-light for MAA. I don't mean Eden needs to be hooked up, validated and running. I believe MHRA already knows it's getting done. The question is, how long will the tweeking take? A month? A year? In the February PR we were told that they had chosen a company to make the Eden units GMP-compatible and it talked like it would take several months to build it. I thought we were ready to go into production, but obviously there have been things that needed tweeking and changing on the prototype. We're obviously there now, with the very definitive statement they made in the 10Q:
Absolutely!
dstock, the last trial that just opened is in ovarian cancer. It was in another paragraph of the 10Q that was just published. And it explains what the first two are, as well. So, those of us, including you and me who have been trying to identify exactly which trials we now own, can probably figure it out exactly. I haven't gone back to Clinical Trials to do this, but please do!
Thanks for your input here on Flaskworks Eden GMP-readiness, Newman. I agree!
Thanks for your professional(I think) opinion, Antihama. It sounds like you have some knowledge on how the company may handle improvements to the Eden units.
Antihama: